NL-OMON38143已完成3 期
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - FE200486 CS29
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Ferring
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Has given written informed consent before any trial-related activity is performed. ;2. Has prostate cancer, and is in need of this type of treatment.
排除标准
- •1. Has had previous or is currently under hormonal treatment of prostate cancer. ;2. Is considered to be candidate for radical prostatectomy or radiotherapy. ;3. Has a history of severe uncontrolled asthma and/or other severe allergic reactions. ;4. Has hypersensitivity towards any component of degarelix. ;5. Has had cancer within the last five years except prostate cancer and some types of skin cancer. ;6. Has a severe disorder (other than prostate cancer) including but not limited to liver, biliary, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, as judged by the investigator.
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - FE200486 CS29Prostate CancerEUCTR2008-003931-19-FRFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
An Open Multi-Centre Trial, Investigating a hormonel drug (Degarelix)given once a month followed by a period without treatment (calledintermittent androgen deprivation) in Patients with Prostate CancerRequiring Androgen Deprivation TherapyProstate CancerEUCTR2008-003931-19-BEFerring Pharmaceuticals A/S220
进行中（未招募）
不适用
An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy - FE200486 CS29Prostate CancerEUCTR2008-003931-19-NLFerring Pharmaceuticals A/S200
进行中（未招募）
不适用
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A - NDFollowing EMEA guidelines NN7008-3545 trial is a prospective clinical phase 3a trial intended at demonstrating safety and efficacy of N8 in previously treated patients < 12 years of age with severe haemophilia A. The trial will continue until at least 50 patients have received at least 50 EDs to the product.MedDRA version: 12.1Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsEUCTR2009-016383-36-ITOVO NORDISK60
进行中（未招募）
1 期
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding during Surgical Procedures in Subjects with Haemophilia AEUCTR2008-003960-20-GBovo Nordisk A/S150